Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis
BK Tan, S Mainbourg, A Friggeri, L Bertoletti… - Thorax, 2021 - thorax.bmj.com
Background The prevalence of venous thromboembolic event (VTE) and arterial
thromboembolic event (ATE) thromboembolic events in patients with COVID-19 remains …
thromboembolic event (ATE) thromboembolic events in patients with COVID-19 remains …
Pulmonary thromboembolic events in COVID‐19—A systematic literature review
PM Overton, M Toshner, C Mulligan, P Vora… - Pulmonary …, 2022 - Wiley Online Library
Pulmonary thromboembolic events have been linked to coronavirus disease 2019 (COVID‐
19), but their incidence and long‐term sequelae remain unclear. We performed a systematic …
19), but their incidence and long‐term sequelae remain unclear. We performed a systematic …
The pleiotropic effects of antithrombotic drugs in the metabolic–cardiovascular–neurodegenerative disease continuum: Impact beyond reduced clotting
Antithrombotic drugs are widely used for primary and secondary prevention, as well as
treatment of many cardiovascular disorders. Over the past few decades, major advances in …
treatment of many cardiovascular disorders. Over the past few decades, major advances in …
Inhaled Edoxaban dry powder inhaler formulations: Development, characterization and their effects on the coagulopathy associated with COVID-19 infection
Herein, we demonstrated the development and characterization of a dry powder inhaler
(DPI) formulation of edoxaban (EDX); and investigated the in-vitro anticoagulation effect for …
(DPI) formulation of edoxaban (EDX); and investigated the in-vitro anticoagulation effect for …
Routine screening for pulmonary embolism in COVID-19 patients at the emergency department: impact of D-dimer testing followed by CTPA
DA Korevaar, I Aydemir, MW Minnema, K Azijli… - Journal of Thrombosis …, 2021 - Springer
COVID-19 patients have increased risk of pulmonary embolism (PE), but symptoms of both
conditions overlap. Because screening algorithms for PE in COVID-19 patients are currently …
conditions overlap. Because screening algorithms for PE in COVID-19 patients are currently …
Overactivation of IL6 cis‑signaling in leukocytes is an inflammatory hallmark of deep vein thrombosis
R Salemi, B Tomasello, G Gattuso… - Molecular …, 2022 - spandidos-publications.com
Inflammation is a protective response of the body to various injuries, which is strictly
regulated by a variety of factors, including immune cells and soluble mediators. However …
regulated by a variety of factors, including immune cells and soluble mediators. However …
Cardiovascular implications of the COVID-19: Management of complications and drug safety concerns
M Hamidian, R Ansari, MM Zarshenas… - Journal of Research …, 2022 - journals.lww.com
Abstract Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory
syndrome coronavirus 2, has rapidly spread worldwide and has been infected more than …
syndrome coronavirus 2, has rapidly spread worldwide and has been infected more than …
[PDF][PDF] Antithrombotic Therapy in COVID-19–A Scientific Position Statement by Heart Disease Management Program, National Health Mission, Government of Tamil …
R Edwin, K Kannan, V Ramachandran… - Journal of the …, 2021 - researchgate.net
The initial damage in persons prone for severe infection occurs in the alveoli evoking an
inflammatory response and microvascular thrombi. There is a “bidirectional cross talk” …
inflammatory response and microvascular thrombi. There is a “bidirectional cross talk” …
[HTML][HTML] Pragmatic Recommendations for the Management of Anticoagulation and Venous Thrombotic Disease for Hospitalized Patients with COVID-19 in Low-and …
HY Ahmed, A Papali, T Haile, GS Shrestha… - The American Journal …, 2021 - ncbi.nlm.nih.gov
New studies of COVID–19 are constantly updating best practices in clinical care. Often, it is
impractical to apply recommendations based on high-income country investigations to …
impractical to apply recommendations based on high-income country investigations to …
New anticoagulant therapy aspects to the COVID-19 patients: From prophylaxis to complications treatment therapy
A Đenić - Medicinski glasnik Specijalne bolnice za bolesti štitaste …, 2021 - scindeks.ceon.rs
COVID-19 patients have a high risk of thrombosis of the arterial and venous systems due to
extensive systemic inflammation, platelet activation, endothelial dysfunction, and stasis. D …
extensive systemic inflammation, platelet activation, endothelial dysfunction, and stasis. D …